Formosa Laboratories Inc
Formosa Laboratories, Inc., together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. The company offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulator… Read more
Formosa Laboratories Inc (4746) - Total Liabilities
Latest total liabilities as of September 2025: NT$4.99 Billion TWD
Based on the latest financial reports, Formosa Laboratories Inc (4746) has total liabilities worth NT$4.99 Billion TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Formosa Laboratories Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how Formosa Laboratories Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Formosa Laboratories Inc Competitors by Total Liabilities
The table below lists competitors of Formosa Laboratories Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UEM Sunrise Bhd
KLSE:5148
|
Malaysia | RM5.78 Billion |
|
Elme Communities
NYSE:ELME
|
USA | $777.68 Million |
|
Nam Tai Property Inc.
PINK:NTPIF
|
USA | $303.19 Million |
|
Taekwang Ind
KO:003240
|
Korea | ₩659.85 Billion |
|
Cellectis SA
NASDAQ:CLLS
|
USA | $242.57 Million |
|
HKFoods Oyj A
HE:HKFOODS
|
Finland | €334.10 Million |
|
Mildef Crete
TWO:3213
|
Taiwan | NT$982.97 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Formosa Laboratories Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Formosa Laboratories Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Formosa Laboratories Inc (2009–2024)
The table below shows the annual total liabilities of Formosa Laboratories Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$5.25 Billion | -3.27% |
| 2023-12-31 | NT$5.43 Billion | +9.52% |
| 2022-12-31 | NT$4.95 Billion | +12.22% |
| 2021-12-31 | NT$4.41 Billion | -11.70% |
| 2020-12-31 | NT$5.00 Billion | -2.93% |
| 2019-12-31 | NT$5.15 Billion | +23.60% |
| 2018-12-31 | NT$4.17 Billion | +32.68% |
| 2017-12-31 | NT$3.14 Billion | +19.39% |
| 2016-12-31 | NT$2.63 Billion | -12.13% |
| 2015-12-31 | NT$2.99 Billion | +12.76% |
| 2014-12-31 | NT$2.66 Billion | +7.27% |
| 2013-12-31 | NT$2.48 Billion | +4.83% |
| 2012-12-31 | NT$2.36 Billion | +91.41% |
| 2011-12-31 | NT$1.23 Billion | +25.63% |
| 2010-12-31 | NT$981.92 Million | +172.92% |
| 2009-12-31 | NT$359.78 Million | -- |